MT9, a natural peptide from black mamba venom antagonizes the muscarinic type 2 receptor and reverses the M2R-agonist-induced relaxation in rat and human arteries.

Arterial pressure Bioactive peptide mass spectrometry M2 muscarinic receptor Peptide folding Peptide sequencing, Drug screening Peptide synthesis Snake venom

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 15 03 2022
revised: 25 04 2022
accepted: 04 05 2022
entrez: 5 6 2022
pubmed: 6 6 2022
medline: 9 6 2022
Statut: ppublish

Résumé

All five muscarinic receptors have important physiological roles. The endothelial M2 and M3 subtypes regulate arterial tone through direct coupling to Gq or Gi/o proteins. Yet, we lack selective pharmacological drugs to assess the respective contribution of muscarinic receptors to a given function. We used mamba snake venoms to identify a selective M2R ligand to investigate its contribution to arterial contractions. Using a bio-guided screening binding assay, we isolated MT9 from the black mamba venom, a three-finger toxin active on the M2R subtype. After sequencing and chemical synthesis of MT9, we characterized its structure by X-ray diffraction and determined its pharmacological characteristics by binding assays, functional tests, and ex vivo experiments on rat and human arteries. Although MT9 belongs to the three-finger fold toxins family, it is phylogenetically apart from the previously discovered muscarinic toxins, suggesting that two groups of peptides evolved independently and in a convergent way to target muscarinic receptors. The affinity of MT9 for the M2R is 100 times stronger than that for the four other muscarinic receptors. It also antagonizes the M2R/G

Identifiants

pubmed: 35658242
pii: S0753-3322(22)00483-8
doi: 10.1016/j.biopha.2022.113094
pii:
doi:

Substances chimiques

Cholinergic Agents 0
Elapid Venoms 0
Peptides 0
Receptors, Muscarinic 0
Toxins, Biological 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113094

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Justyna Ciolek (J)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.

Claude Zoukimian (C)

Smartox Biotechnology, 6 rue des platanes, 38120 Saint-Egrève, France.

Justine Dhot (J)

Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Mélanie Burban (M)

Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Mathilde Triquigneaux (M)

Smartox Biotechnology, 6 rue des platanes, 38120 Saint-Egrève, France.

Benjamin Lauzier (B)

Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Christelle Guimbert (C)

Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Didier Boturyn (D)

CNRS UMR 5250, Université Grenoble Alpes, Institut de Chimie Moléculaire de Grenoble, Bâtiment NANOBIO, 38041 Grenoble, France.

Marine Ferron (M)

Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Lidia Ciccone (L)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France; Société civile Synchrotron SOLEIL, L'orme des Merisiers Saint-Aubin - BP48, Gif-sur-Yvette, 91192, France.

Livia Tepshi (L)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.

Enrico Stura (E)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.

Pierre Legrand (P)

Société civile Synchrotron SOLEIL, L'orme des Merisiers Saint-Aubin - BP48, Gif-sur-Yvette, 91192, France.

Philippe Robin (P)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.

Gilles Mourier (G)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.

Béatrice Schaack (B)

Université Grenoble Alpes, CNRS, INP, TheRex Team, TIMC-IMAG, F-38700 La Tronche, France.

Imen Fellah (I)

Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Guillaume Blanchet (G)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.

Chantal Gauthier-Erfanian (C)

Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Rémy Beroud (R)

Smartox Biotechnology, 6 rue des platanes, 38120 Saint-Egrève, France.

Denis Servent (D)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.

Michel De Waard (M)

Smartox Biotechnology, 6 rue des platanes, 38120 Saint-Egrève, France; Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France; LabEx " Ion Channels, Science and Therapeutics ", Valbonne F-06560, France. Electronic address: michel.dewaard@univ-nantes.fr.

Nicolas Gilles (N)

Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France. Electronic address: nicolas.gilles@cea.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH